NCH 51, HDAC inhibitor

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

HDAC1 HDAC4 and HDAC6 are histone deacetylases enzymes involved in removing acetyl groups from lysine residues on histone proteins. This activity influences chromatin structure and gene expression by transcription repression. HDAC1 also known as RPD3L1 has a molecular weight of approximately 55 kDa whereas HDAC4 and HDAC6 are larger around 110 kDa and 131 kDa respectively. HDAC1 and HDAC4 are predominantly in the nucleus while HDAC6 mainly localizes in the cytoplasm. The expression of these proteins can be tissue-specific with significant presence in heart pancreas and brain.

Biological function summary

These HDAC proteins play critical roles in regulating cellular processes such as cell cycle apoptosis and differentiation. HDAC1 is a component of several multiprotein complexes including the Sin3 and NuRD complexes which target chromatin for modulating gene expression. HDAC4 is involved in transcriptional repression associated with muscle and neuronal development. HDAC6 regulates cytoskeleton dynamics primarily through the deacetylation of tubulin. These functions indicate the diverse roles that HDACs can have at cellular level.

Pathways

HDACs are integral to significant regulatory pathways like cell cycle control and the p53 signaling pathway. HDAC1 interacts with the retinoblastoma protein contributing to cell cycle regulation and tumor suppression. HDAC4 engages in the calcineurin/NFAT pathway relevant for neuronal survival and plasticity. HDAC6 participates in the heat shock protein 90 (HSP90) pathway which is important for the degradation of misfolded proteins thereby interacting with cochaperones and other proteins like tau.

Irregular HDAC activity links to various cancers and neurodegenerative diseases. Overexpression of HDAC1 and HDAC4 associates with certain cancers by altering gene expression conducive to oncogenesis. Meanwhile HDAC6 has connections to neurodegenerative conditions like Alzheimer's disease where it interacts with tau protein contributing to toxic aggregation in neurons. Drugs targeting these HDACs known as HDAC inhibitors represent a therapeutic strategy in treating these conditions leveraging their mechanistic pathways to restore normal cellular function.